Loading…
Maker of single-use medical devices for vascular access, surgical, interventional and urology procedures.
Maker of single-use medical devices for vascular access, surgical, interventional and urology procedures.
Sells disposable devices that are used once per procedure, so revenue recurs with procedure volumes rather than depending on one-off equipment sales. Hospitals buy through its own sales force, distributors and supply contracts. Its vascular access and interventional lines carry the business.
Moat: narrow (scale, switching costs, installed base). Broad catalog of clinically embedded single-use devices with established hospital contracts.
Headquarters: Wayne, Pennsylvania, USA · Founded: 1943 · Employees: 15,500
Size Teleflex (TFX) is a United States Health Care company (Medical Specialties) with a market value of $6.39B, the 1013th largest of 3,117 United States companies the cockpit tracks. Shares closed at $150.87 on 6 Nov 2026.
Performance Over six months the shares gained 13.4%, against +27.7% for the median peer and -1.1% for the United States market (cap-weighted) — 5th lowest of 21 in its peer set.
Growth Revenue fell 14.5% over the last twelve months (peer median +6.3%); the operating margin is 11.0% (peer median 15.1%).
Valuation It trades at 16.8× forward earnings against a peer median of 21.0× (4th cheapest of 20).
Price implies For today's price to make sense, revenue must grow about 18% a year for seven years (Req g). Recent delivered growth is -5%, so the hurdle is +23 pp: the price needs faster growth than the company has been delivering — of companies that just grew 25–50% a year, 93.8% slowed down over the next four years.
Capital Return on invested capital runs 3.8 points below its cost of capital (8.0% WACC).
Credit Teleflex has 1 bond outstanding ($500M), rated BB by the agencies and trading like BBB- at a weighted spread of 122 bp.
Short interest Short interest is 9.9% of the free float (15 Oct 2026).
Next results Next results expected around 25 Feb 2027 (exchange calendar; dates can move).
| TTM | FY2025 | FY2024 | FY2023 | FY2022 | |
|---|---|---|---|---|---|
| Revenue | $2.60B | $1.99B | $1.70B | $2.97B | $2.79B |
| Revenue growth | — | +17% | -43% | +7% | — |
| Gross profit | $1.58B | $1.13B | $1.04B | $1.65B | $1.56B |
| EBITDA | $435M | $455M | $414M | $816M | $778M |
| Net income | -$1.03B | -$906M | $69.7M | $356M | $363M |
| Free cash flow | $340M | $245M | $545M | $419M | $264M |
| Capital expenditure | $63.4M | $95.2M | $90.4M | $91.4M | $79.2M |
| Total debt | $2.87B | $2.73B | $1.74B | $1.95B | $1.85B |
The default views of Competitor Analysis ▸ Charts, drawn from the same data. Open them in the cockpit to change the axes, pin companies and read every value.
| Company | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g |
|---|---|---|---|---|---|---|
| Teleflex TFX | $6.39B | +13% | -14% | 11% | 16.8× | 17.8% |
| Becton Dickinson BDX | $57.7B | +43% | -3% | 15% | 16.0× | 9.6% |
| Medtronic MDT | $130B | +35% | +10% | 20% | 16.9× | 8.6% |
| ICU Medical ICUI | $4.30B | +36% | -9% | 7% | 19.5× | 22.1% |
Peer set: Industry: the same industry and sector in any market, nearest in size. This is the same default set the interactive Competitor Analysis opens with.
| Measure | TFX | Peer median | Rank in peer set |
|---|---|---|---|
| 1-month return | +21.5% | +9.1% | 2nd highest of 21 |
| 6-month return | +13.4% | +27.7% | 5th lowest of 21 |
| Distance from 52-week high | -3.7% | -9.8% | 5th highest of 21 |
| Revenue growth (TTM) | -14.5% | +6.3% | lowest of 21 |
| Operating margin | 11.0% | 15.1% | 4th lowest of 21 |
| Forward P/E | 16.8× | 21.0× | 4th cheapest of 20 |
| Growth the price implies (Req g, 7 yrs) | 17.8% | 10.9% | 3rd most demanding of 19 |
| Growth delivered (Del g) | -4.7% | +9.4% | 2nd lowest of 19 |
| Hurdle (Req g minus delivered) | +22.5 pp | +1.2 pp | most demanding of 19 |
| ROIC minus cost of capital | -3.8 pp | +3.4 pp | 2nd lowest of 21 |
| EV / EBITDA | 20.6× | 14.2× | 2nd most expensive of 17 |
| Net debt / EBITDA | 5.9× | 0.9× | most indebted of 17 |
| Bond spread | 122 bp | n/a | — |
| Company | Market | Market cap | 6M return | Revenue growth | Op. margin | Forward P/E | Req g | Delivered g |
|---|---|---|---|---|---|---|---|---|
| Teleflex TFX | United States | $6.39B | +13% | -14% | 11% | 16.8× | 17.8% | -4.7% |
| ConvaTec CTEC.L | United Kingdom | $6.44B | +22% | +2% | 16% | 16.7× | 15.6% | +4.6% |
| Ypsomed YPSN.SW | Switzerland | $6.35B | +30% | -2% | 25% | 30.1× | 11.5% | +12.6% |
| Asahi Intecc 7747.T | Japan | $6.28B | +13% | +21% | 31% | 26.0× | 13.6% | +18.8% |
| Lantheus LNTH | United States | $6.57B | +8% | +2% | 19% | 17.5× | -0.5% | +35.3% |
| APT Medical 688617.SS | China | $5.95B | +20% | +28% | 37% | 38.5× | 8.7% | +40.1% |
| Cochlear COH.AX | Australia | $7.05B | +55% | -1% | 13% | 29.4× | 24.1% | +9.3% |
| Shenzhen New Industries Biomedical Engineering 300832.SZ | China | $7.11B | +25% | +7% | 43% | 25.5× | 2.1% | +15.7% |
| Bausch + Lomb BLCO.TO | Canada | $7.20B | +31% | +11% | 9% | 17.3× | 11.0% | +10.0% |
| Haemonetics HAE | United States | $5.46B | +118% | 0% | 18% | 21.6× | 10.9% | +8.9% |
| GRAIL GRAL | United States | $5.42B | +67% | +23% | -323% | n/a | n/a | n/a |
| Getinge GETI-B.ST | Sweden | $7.73B | +45% | -4% | 14% | 21.0× | 4.7% | +3.2% |
| Shimadzu 7701.T | Japan | $7.79B | +15% | +6% | 13% | 19.5× | 6.3% | +7.3% |
| Merit Medical Systems MMSI | United States | $5.23B | +42% | +9% | 14% | 19.4× | 12.2% | +9.5% |
| Sysmex 6869.T | Japan | $7.89B | +50% | +4% | 13% | 31.2× | 4.4% | +10.4% |
| DiaSorin DIA.MI | Italy | $5.00B | +19% | -3% | 24% | 20.6× | 4.1% | +6.3% |
| LivaNova LIVN | United States | $4.96B | +25% | +12% | 13% | 19.9× | 11.5% | +8.2% |
| MiniMed MMED | United States | $4.70B | +44% | +14% | 14% | 25.5× | n/a | n/a |
| Sotera Health SHC | United States | $4.57B | +1% | +7% | 37% | 15.4× | 13.7% | +7.3% |
| Intco Medical Technology 300677.SZ | China | $4.40B | -20% | +33% | 20% | 14.7× | -4.7% | -6.4% |
| Bruker BRKR | United States | $9.34B | +39% | +2% | 9% | 26.2× | 25.7% | +11.6% |
Teleflex has 1 bond outstanding with $500M face value. The agencies rate it BB; its bonds trade like BBB-. Weighted yield 5.72%, a spread of 122 bp over government bonds.